Mechanisms and Therapeutic Approaches for Hepatocellular Carcinoma

Dear Colleagues,

Hepatocellular carcinoma (HCC) is the most prevalent histological subtype of primary liver cancer, with a high global incidence and mortality, contributing to a critical global health burden. Despite advances in early diagnosis and treatment, HCC remains challenging to manage due to the high recurrence rate, limited therapy options for intermediate- and advanced-stage patients, and unsatisfactory responses following repeated treatments. There is an urgent need for basic, translational, and clinical studies that identify novel and safe therapeutic approaches for HCC and improve our understanding of the molecular mechanisms that drive treatment responses, therapeutic resistance, and tumor progression.

This Special Issue aims to provide a valuable platform for researchers and clinicians to present their latest findings and insights on the molecular mechanisms and novel therapeutic approaches for HCC. We aim to bring together a diverse group of experts in HCC research to provide a comprehensive overview of the current progress, identify promising directions for future research, and contribute to developing effective and personalized therapies for HCC that can ultimately improve patient outcomes. We welcome original research articles, reviews, communications, and perspectives that cover a broad range of topics related to HCC, including but not limited to the following:

• The molecular mechanisms of HCC pathogenesis and progression;
• Biomarkers for early diagnosis and prognosis of HCC;
• Novel therapeutic targets and drugs for HCC treatment;
• Immunotherapy and targeted therapy for HCC;
• Personalized medicine for HCC;
• Pre-clinical and clinical studies on novel therapeutic approaches for HCC.

Dr. Lanqi Gong
Prof. Dr. Xinyuan Guan
Dr. Yu Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hepatocellular carcinoma
• HCC diagnosis and prognosis
• HCC mechanisms
• therapeutic resistance
• immunotherapy
• targeted therapy
• personalized medicine
• drug development
• clinical trials
• translational studies